CJC-1295 side effects: what the studies found
Real adverse event rates, clinical trial discontinuation numbers, and documented safety warnings from peer-reviewed literature.
This page has not yet been reviewed by a credentialed medical professional. It is educational and is not medical advice.
Safety summary: CJC-1295
- Evidence level Human trials
- FDA approvedNo
- Trial discontinuationPhase 1/2 volunteer trials had low discontinuation, but development was discontinued by the manufacturer.
- WADA sport statusProhibited
In short: Short trials reported no serious adverse reactions, but they involved few people over weeks. Raising GH and IGF-1 long term raises theoretical concerns (fluid retention, joint pain, insulin resistance) known from GH therapy; these have not been characterised for CJC-1295 specifically.
Not approved by the FDA. Prohibited at all times in sport by WADA under Category S2.
Most common side effects
Reported symptoms in clinical trials and published pharmacology literature:
| Symptom | Reported rate | Clinical context & notes |
|---|---|---|
| Facial flushing | Very common in trials | Transient warm sensation and redness lasting 10 to 30 minutes following injection. |
| Injection site induration or pain | Common | Localized swelling, redness, and itching at the subcutaneous injection site. |
| Headache | Common | Typically mild and transient after administration. |
| Transient hypotension | Reported in Phase 1 trials | Mild, temporary drop in blood pressure immediately post-injection. |
Serious risks and warnings
Potential adverse reactions and biological risks identified in research:
- Fluid retention & peripheral edema: Sustained elevation of GH and IGF-1 can cause fluid retention, extremity swelling, and joint stiffness.
- Carpal tunnel syndrome symptoms: Nerve compression from soft tissue swelling associated with elevated growth hormone.
- Insulin resistance: Growth hormone counteracts insulin action; chronic elevation can impair glucose tolerance.
- Mitogenic risk in occult neoplasia: IGF-1 stimulates cellular proliferation and inhibits apoptosis, raising concerns in pre-malignant conditions.
Contraindications
This compound should not be used in individuals with:
- Active malignancy or history of pituitary adenoma
- Pre-existing carpal tunnel syndrome or severe edema
- Competitive athletes under WADA drug testing
Common questions about CJC-1295 safety
Why was clinical development of CJC-1295 stopped?
CJC-1295 was originally developed by ConjuChem. In a Phase 2 trial combining it with other agents, a patient death from a cardiac event occurred, prompting clinical trials to be halted. While the direct causal relationship was debated, commercial development ceased.
Does CJC-1295 raise blood sugar?
Yes, prolonged elevation of growth hormone can cause insulin resistance. In healthy volunteers, short-term administration showed modest fluctuations, but long-term unmonitored use can worsen glucose tolerance.
What is the difference between CJC-1295 with and without DAC?
CJC-1295 with DAC (Drug Affinity Complex) binds to albumin and has a half-life of 6 to 8 days, causing continuous GH release. CJC-1295 without DAC (modified GRF 1-29) has a half-life of roughly 30 minutes and causes a single brief pulse.